SASatoshi Asai

Satoshi Asai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Satoshi Asai has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural Changes in the Cerebral Cortex with Hepatitis C Virus Infection

    by Junko Kikuta, Akihiko Wada, Hiroki Haradome, Yayoi Nishida, Yasuo Takahashi, Satoshi Asai, Yasuo Amano, Osamu Abe

    C 型肝炎ウイルス (HCV) は,慢性肝炎や肝硬 変などの肝疾患の起因としてよく知られているが,その 他 30 以上のウイルス関連性の肝外疾患が存在する.最 近では,HCV 感染による中枢神経系への直接的・間接 的障害が注目されている.本研究では,慢性 C 型肝炎患 者を対象として,頭部 MRI 画像を用いた大脳皮質の形 態的変化を検討した.疾患群は慢性 C 型肝炎患者 11 人, 対照群は 18 人であった.頭部 MRI 画像を元に,Surfacebased morphometry (SBM) の一つである FreeSurfer で大 脳皮質表面を再構築し,Query, Design, Estimate, and Contrast (QDEC) 解析法を用いて大脳皮質を疾患群と対照群 との間で比較した.その結果,疾患群では対照群と比較 して,左中側頭回,左上側頭回,左上前頭回,右中心後 回に皮質表面積の有意な低下 (P < 0.001),右下頭頂小葉 に皮質厚の有意な増加を認めた (P < 0.001).従って,慢 性 C 型肝炎患者において言語領域を主体とした大脳皮 質の形態的変化が認められ,HCV 感染によって惹起さ れた中枢神経障害を示唆するものと考えられた.

  • Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study

    by Norio Susa, Yayoi Nishida, Yoichi Yada, Tomohiro Nakayama, Satoshi Asai, Yasuo Takahashi

    We conducted a retrospective cohort study to evaluate and compare the long-term effects of two single-pill fixed-dose combinations (FDCs), candesartan/amlodipine and olmesartan/azelnidipine, on laboratory parameters in patients in routine clinical practice. We identified an equal number of new users (n = 182) of a candesartan/amlodipine (8/5 mg/day) FDC tablet (CAN/AML users) and a propensity-score matched cohort (n = 182) receiving an olmesartan/azelnidipine (20/16 mg/day) FDC tablet (OLM/AZ users). Generalized estimating equations were used to estimate and compare the effects of the drugs on serum levels of creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), uric acid, sodium, potassium, aspartate aminotransferase, and alanine aminotransferase levels up to 12 months after the start of study drug administration. There was a significant increase of serum creatinine level and a significant decrease of eGFR from the baseline period to during the exposure period in both CAN/AML and OLM/AZ users, and a significant increase of BUN level in CAN/AML users. However, there were no significant differences in the mean changes of laboratory parameters between CAN/AML and OLM/AZ users. Our findings suggested that the effects of CAN/AML and OLM/AZ on laboratory parameters, including an unfavorable effect on renal function, were similar at least during 1 year of administration.


  • Liver function assessment with three13C breath tests by two-point measurements

    by Yukimoto Ishii, Shigeru Suzuki, Satoshi Asai, Ichirou Murai

    In this study, we performed three breath tests – l-[1-13C ]phenylalanine breath test (PBT), l-[1-13C ] methionine breath test, and [13C]methacetin breath test (MethaBT) – in patients with chronic liver disease to determine the optimal timing of expired air collection for diagnosing chronic liver disease and evaluating the grade of fibrosis. The subjects were 61 adults with normal livers, 98 chronic hepatitis patients, and 91 liver cirrhosis patients. We investigated the relationships of breath test results with routine biochemical tests and the Child–Pugh score, as well as the diagnostic capacities of the breath tests for liver dysfunction/cirrhosis and grade of liver fibrosis. For the diagnosis of liver cirrhosis and correlations with liver fibrosis, the accuracy of the PBT at 30 min (PBT30) was similar to that of the MethaBT at 15 min (Metha15). For liver function assessment by two-point measurement with 13C breath tests, we recommend the PBT30 and the Metha15.


    • 1 February 2011
      • Vol. 59  (2) , 128-33

    Identifying unrecognized airflow obstruction in cases with lifestyle-related diseases using a data mining system with electronic medical records.

    by Ken Matsumoto, Yasuo Takahashi, Yasuhiro Gon, Toshiki Akahoshi, Tomohiro Nakayama, Satoshi Asai, Shu Hashimoto

    Airflow obstruction is the most important pathophysiologic factor in chronic obstructive pulmonary disease (COPD). Although the prevalence of airflow obstruction has been increasing worldwide, airflow obstruction is often under-recognized in clinical practice because of insufficient use of spirometry. The aim of the present study was to identify unrecognized airflow obstruction in cases with lifestyle-related diseases using a data mining system that we have developed for use with electronic medical records. Clinical, spirometric data on 27,111 patients aged 40 years or older treated during the period from January 1999 to December 2008 was retrospectively collected from the electronic medical records of the Nihon University School of Medicine clinical data warehouse. Airflow obstruction was defined according to the criteria established by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Of the 27,111 patients, 6,098 (22.5%) showed airflow obstruction. Airflow obstruction was significantly more frequent in males, the elderly and smokers. The prevalence of airflow obstruction in patients with atherosclerosis (29.3%) was greater than that in patients with dyslipidemia (24.3%), diabetes mellitus (23.1%) or hypertension (27.1%). Only 14% of patients with airflow obstruction had a previous diagnosis of COPD. Latent COPD patients with airflow obstruction are highly prevalent, not only in those over 70 years of age with lifestyle-related diseases, but also in middle-aged patients. Spirometry should be widely used for patients with lifestyle-related diseases and a history of smoking, to effectively detect undiagnosed COPD.


  • Open Access

    Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records

    by Yayoi Nishida, Yasuo Takahashi, Tomohiro Nakayama, Masayoshi Soma, Noboru Kitamura, Satoshi Asai

    Background: Studies focusing on the add-on effects of angiotensin II type 1 receptor blockers (ARBs) other than their antihypertensive effect are receiving attention. However, the effects of prolonged administration of ARBs on lipid metabolism in clinical cases are unclear. Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan. Methods: We carried out candesartan monotherapy in patients with mild to moderate hypertension and examined the longitudinal changes in plasma lipid profile. Data from 405 patients for triglyceride (TG), 440 for total cholesterol (TC), 313 for high density lipoprotein cholesterol (HDL-C) and 304 for low density lipoprotein cholesterol (LDL-C) were obtained from the electronic medical records (EMRs) in the Clinical Data Warehouse (CDW) of Nihon University School of Medicine (NUSM). The inverse probability of treatment weighting (IPTW) method (calculated from the inverse of the propensity score) was used to balance the covariates and reduce bias in each treatment duration. Linear mixed effects models were used to analyse the relationship between these longitudinal data of blood examinations and covariates of patient sex, age, diagnosis of diabetes mellitus (DM) and duration of candesartan monotherapy. Results: Plasma HDL-C level was associated with sex, duration of treatment, and interaction of sex and treatment duration, but not with age or diagnosis of DM. HDL-C level was significantly decreased during the 6~9 months period (p = 0.0218) compared with baseline. TG and TC levels were associated with sex, but not with age, diagnosis of DM or treatment duration. LDL-C level was not associated with any covariate. Analysis of the subjects divided by sex revealed a decrease in HDL-C in female subjects (during the 6~9 months period: p = 0.0054), but not in male subjects. Conclusions: Our study revealed that administration of candesartan slightly decreased HDL-C in female subjects. However, TG, TC and LDL-C levels were not influenced by candesartan monotherapy. Candesartan may be safely used for patients with hypertension with respect to lipid metabolism, because the effect of candesartan on lipids may be small.


  • Open Access

    Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records

    by Noboru Kitamura, Yasuo Takahashi, Shuukoh Yamadate, Satoshi Asai

    Background: A beneficial effect on glucose metabolism is reported with angiotensin receptor blocker (ARB) treatment of hypertension. The effect on blood glucose level during the course of treatment with ARBs in clinical cases is uncertain. Our objectives were to survey the changes in glucose and HbA1c levels in patients with hypertension over a one-year period, and to study the correlations between these values and the time after the start of ARB therapy. Methods: We conducted a retrospective longitudinal survey of blood glucose and HbA1c measurements in Japanese patients aged ≥20 years with newly diagnosed hypertension but without diabetes, who had received ARB monotherapy with candesartan cilexetil, losartan potassium, olmesartan medoxomil, telmisartan, or valsartan during the period from December 2004 to November 2005. Data including 2465 measurements of non-fasting blood glucose in 485 patients and 457 measurements of HbA1c in 155 patients were obtained from electronic medical records of Nihon University School of Medicine. Linear mixed effects models were used to analyze the relationship between these longitudinal data of blood examinations and covariates of patient age, sex, medication, and duration of ARB therapy. Results: Casual blood glucose level was associated with the duration of treatment (P < 0.0001), but not with age, sex, or medication. Blood glucose level was significantly decreased during the periods of 0~3 months (P < 0.0001) and 3~6 months (P = 0.0081) compared with baseline, but was not significantly different between 6~12 months and baseline. There was no association between HbA1c level and covariates of sex, age, medication and duration of treatment. Conclusion: Our findings provide new clinical evidence that the effects of ARBs on glucose metabolism may change during the course of treatment, suggesting a blood glucose-lowering effect in the short-term after the start of treatment.


  • Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis

    by Kimitoshi Kato, Yukimoto Ishii, Shigeaki Mizuno, Masahiko Sugitani, Satoshi Asai, Tadashi Kohno, Katsuyuki Takahashi, Sachiko Komuro, Maho Iwamoto, Shunpachi Miyamoto, et al.

    Objective. Impaired butyrate metabolism plays a part in ulcerative colitis (UC). To assess the usefulness of measuring butyrate metabolism as an indication of inflammatory activity, we investigated the rate of butyrate metabolism by breath test after administering [1-13C]-butyrate rectally to patients with UC. Material and methods. Thirty-eight UC patients (22 active, 16 quiescent) and 15 healthy controls were given [1-13C]-butyrate enemas. The 13CO2 production rate was measured by breath test using an infrared spectrometric analyzer. Results. The quantity of expired 13CO2 was significantly lower in the active than in the quiescent UC and control groups. Cumulative 13CO2 production at 240 min showed significant negative correlations with the clinical activity index (r= −0.65, pr= −0.63, p=0.0001) and histology (r= −0.71, p13CO2 production rate was significantly increased in the quiescent stage as compared with the active stage in six UC patients, in whom clinical remission was achieved, in accordance with improvements in the clinical activity index, the endoscopic activity index, histology and fecal butyrate concentrations. Significant inverse correlations between the cumulative 13CO2 production rate and these three parameters were seen in these six UC patients assessed in both the active and quiescent stages. Conclusions. Measurement of expired 13CO2 after rectally administering [1-13C]-butyrate in active and quiescent UC appears to be a promising and reliable method for evaluating disease activity and metabolic changes associated with amelioration of inflammation.


  • Statistical Validation of Two Sample Comparison Methods for Oligonucleotide Microarray in Rat Ischemia Model

    by Megumi Sugahara Kobayashi, Yasuo Takahashi, Toshihito Nagata, Yayoi Nishida, Koichi Ishikawa, Satoshi Asai


  • Open Access

    Screening for Control Genes in Mouse Hippocampus After Transient Forebrain Ischemia Using High-Density Oligonucleotide Array

    by Yayoi Nishida, Megumi Sugahara-Kobayashi, Yasuo Takahashi, Toshihito Nagata, Koichi Ishikawa, Satoshi Asai

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Haplotype-Based case-control study of the STRK1 region on 5q12 in cerebral infarction

    by Tomohiro Nakayama, Satoshi Asai, Naoyuki Sato, Masayoshi Soma